FDA 483 - Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. (FDF Site) - April 03, 2018
Discuss this record with AI
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.
An FDA inspection of Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. in Nanjing, China, revealed significant deficiencies in their manufacturing processes for sterile drug products. Observations included inadequate procedures for preventing microbiological contamination, deficiencies in environmental monitoring within aseptic processing areas, and a lack of validated control procedures for manufacturing processes. Additionally, the firm failed to adequately qualify suppliers for containers and closures by not verifying test results.
- Inspection Date
- April 3, 2018
- Product Type
- Drugs
ID · 5067c57b-7e67-4f78-87ab-a42f4d4b0b5c